ID

13744

Description

A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01034410

Lien

https://clinicaltrials.gov/show/NCT01034410

Mots-clés

Versions (1)
  1. 02/03/2016 02/03/2016 -
Détendeur de droits

CC BY-NC 3.0

Téléchargé le

2 mars 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Acute Myeloid Leukemia NCT01034410

Anglais

Eligibility Acute Myeloid Leukemia NCT01034410

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of aml as defined by the world health organization (who) classification (vardiman 2009)
Description

diagnosis of aml as defined by the world health organization (who) classification (vardiman 2009)

Type de données

boolean

Alias
UMLS CUI [1]
C0023467
primary refractory aml (defined as a failure to achieve a cr or cri after therapy with curative intent) or aml in first relapse
Description

primary refractory aml (defined as a failure to achieve a cr or cri after therapy with curative intent) or aml in first relapse

Type de données

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C0205269
ecog performance status 0, 1 or 2
Description

ecog performance status 0, 1 or 2

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
age > 18 and < 70 years
Description

age > 18 and < 70 years

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
for patients presenting with primary refractory aml, > 20% blasts on baseline bone marrow assessment
Description

for patients presenting with primary refractory aml, > 20% blasts on baseline bone marrow assessment

Type de données

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C0205269
UMLS CUI [2]
C1982687
for patients presenting with relapsed aml, > 5% blasts on baseline bone marrow assessment
Description

for patients presenting with relapsed aml, > 5% blasts on baseline bone marrow assessment

Type de données

boolean

Alias
UMLS CUI [1]
C1982687
UMLS CUI [2,1]
C0023467
UMLS CUI [2,2]
C0277556
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
an initial diagnosis of acute promyelocytic leukemia (as defined by french-american-british criteria (bennett 1976))
Description

an initial diagnosis of acute promyelocytic leukemia (as defined by french-american-british criteria (bennett 1976))

Type de données

boolean

Alias
UMLS CUI [1]
C0023487
secondary aml, defined as aml evolving from antecedent hematological disorder or prior exposure to leukemogenic therapy or agent
Description

secondary aml, defined as aml evolving from antecedent hematological disorder or prior exposure to leukemogenic therapy or agent

Type de données

boolean

Alias
UMLS CUI [1]
C0280449
clinically active cns leukemia
Description

clinically active cns leukemia

Type de données

boolean

Alias
UMLS CUI [1]
C1332884
previously received a total cumulative dose of cytarabine > 6g/m2 in the last 6 months
Description

previously received a total cumulative dose of cytarabine > 6g/m2 in the last 6 months

Type de données

boolean

Alias
UMLS CUI [1,1]
C0010711
UMLS CUI [1,2]
C2986497
previously received > 1 induction regimen (defined as 1 or 2 cycles of a drug or a drug combination administered as remission induction therapy)
Description

previously received > 1 induction regimen (defined as 1 or 2 cycles of a drug or a drug combination administered as remission induction therapy)

Type de données

boolean

Alias
UMLS CUI [1]
C3179010
Retour au début de la page

Similar models

Eligibility Acute Myeloid Leukemia NCT01034410

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
AML
Item
diagnosis of aml as defined by the world health organization (who) classification (vardiman 2009)
boolean
C0023467 (UMLS CUI [1])
AML refractory
Item
primary refractory aml (defined as a failure to achieve a cr or cri after therapy with curative intent) or aml in first relapse
boolean
C0023467 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
ECOG
Item
ecog performance status 0, 1 or 2
boolean
C1520224 (UMLS CUI [1])
age
Item
age > 18 and < 70 years
boolean
C0001779 (UMLS CUI [1])
blasts on baseline bone marrow
Item
for patients presenting with primary refractory aml, > 20% blasts on baseline bone marrow assessment
boolean
C0023467 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C1982687 (UMLS CUI [2])
relapsed aml
Item
for patients presenting with relapsed aml, > 5% blasts on baseline bone marrow assessment
boolean
C1982687 (UMLS CUI [1])
C0023467 (UMLS CUI [2,1])
C0277556 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
acute promyelocytic leukemia
Item
an initial diagnosis of acute promyelocytic leukemia (as defined by french-american-british criteria (bennett 1976))
boolean
C0023487 (UMLS CUI [1])
secondary aml
Item
secondary aml, defined as aml evolving from antecedent hematological disorder or prior exposure to leukemogenic therapy or agent
boolean
C0280449 (UMLS CUI [1])
cns leukemia
Item
clinically active cns leukemia
boolean
C1332884 (UMLS CUI [1])
cumulative dose cytarabine
Item
previously received a total cumulative dose of cytarabine > 6g/m2 in the last 6 months
boolean
C0010711 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
induction regimen
Item
previously received > 1 induction regimen (defined as 1 or 2 cycles of a drug or a drug combination administered as remission induction therapy)
boolean
C3179010 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial